Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

Winter 2021
Pro Bono Publico–For The Public Good
Tim Billion, Lindsey Hanson - The Robins Kaplan Spotlight, Vol. 5, No. 4
Winter 2021
The Case for Charitable Giving
Matthew Frerichs - The Robins Kaplan Spotlight, Vol. 5, No. 4
Winter 2021
The Fictional Wealth Disputes That We Took In and Learned From in 2020
Ena Kovacevic - The Robins Kaplan Spotlight, Vol. 5, No. 4
Fourth Quarter
ANDA Approvals
GENERICally Speaking Winter 2021
Back to Top